<DOC>
	<DOCNO>NCT00321347</DOCNO>
	<brief_summary>Opioid medicine , like morphine , main treatment severe cancer pain . Unfortunately , patient suffer severe pain despite high dos opioids . We hypothesize intravenous lidocaine quickly effectively treat kind opioid-refractory pain .</brief_summary>
	<brief_title>Intravenous ( IV ) Lidocaine Opioid-refractory Pain</brief_title>
	<detailed_description>Pain pervasive symptom among advanced cancer patient . In addition pain 's negative impact , unrelieved pain link depression precludes patient deal aspect life . The World Health Organization 3-step hierarchy pain management effective control cancer pain 70-90 % patient . However , significant fraction cancer patient continue suffer severe pain despite high dose opioid therapy . This opioid-refractory pain require adjunctive pain medication . Often multiple adjunctive agent need concurrently optimally control opioid-refractory pain . Unfortunately , patient remain pain time need titrate agent , patient n't time death . Clinically , exist widely available , acute intervention quickly control opioid-refractory pain . Intraspinal delivery medication , peripheral nerve block , neurolysis help subset well-localized pain syndrome , invasive , require subspecialty skill . Sedation quickly relieve pain robs patient ability interact . The hypothesis test study intravenous ( IV ) lidocaine acutely palliate opioid-refractory pain . IV lidocaine show effective small trial non-cancer patient condition post-herpetic neuralgia diabetic neuropathy . Additionally , case report efficacy IV lidocaine cancer patient opioid-refractory pain . However , randomize , placebo-controlled trial cancer patient establish efficacy . Moreover , lidocaine 's pro-arrhythmic potential relatively narrow therapeutic window , theoretical risk harm . As practical matter fact , IV lidocaine available vast majority cancer patient US . To illuminate situation , double-blind , randomize , placebo-controlled , study conduct determine efficacy IV lidocaine acutely relieve severe opioid-refractory pain advance cancer patient . Secondary end-points include analysis safety clinical parameter predictive lidocaine response . The expected outcome lidocaine acutely , effectively , safely relieve opioid-refractory pain . This outcome significantly add evidence-based clinical armamentarium available treat opioid-refractory pain significantly improve cancer patient ' quality life .</detailed_description>
	<mesh_term>Pain , Intractable</mesh_term>
	<mesh_term>Lidocaine</mesh_term>
	<criteria>Inclusion Criteria Advanced cancer patient ( prognosis ≤6 mo ) Age ≥ 18 year old Opioidrefractory pain Steady state level adjunctive pain medication Intravenous access Has decisionmaking capacity Hemodynamics : 85 &lt; SBP &lt; 210 mm Hg &amp; 55 &lt; HR &lt; 120 EKG QTc ≤ 440 msec Exclusion Criteria Methadone use Myoclonus Seizure disorder History ventricular arrhythmia Allergy amide local anesthetic Evidence cardiac ischemia history EKG Currently receive parenteral local anesthetic Pregnancy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>Cancer</keyword>
	<keyword>Pain</keyword>
	<keyword>Lidocaine</keyword>
</DOC>